# OnCo record libretto-431 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/libretto-431/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "libretto-431", "NCT04194944" ;
  schema:name "LIBRETTO-431"@en ;
  schema:description "Proved that a RET pill is better than chemotherapy with or without immunotherapy as first treatment for RET-fusion lung cancer."@en ;
  schema:url <https://onco.cc/trials/libretto-431/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04194944> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2020-02-17" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/ret-fusion-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ret/> ;
  onco:drugs <https://onco.cc/drugs/selpercatinib/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-libretto-431-nejm-2023/> .